Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12‐week randomized, double‐blinded, placebo‐controlled phase 2b trial

Background Neutralizing interleukin (IL) 17F in addition to IL‐17A might provide a more complete and specific approach to inhibiting inflammation. Objective Assess the efficacy and safety of bimekizumab, a monoclonal antibody that potently and selectively neutralizes IL‐17A and IL‐17F, in patients with moderate‐to‐severe plaque psoriasis. Methods Double‐blinded, placebo‐controlled phase 2b study (NCT02905006). Patients (randomized 1:1:1:1:1:1) received subcutaneous bimekizumab every 4 weeks at doses of 64 mg, 160 mg, 160 mg with 320 mg loading dose, 320 mg, 480 mg, or placebo. Primary endpoint was ≥90% reduction in Psoriasis Area Severity Index (PASI90) at week 12. Results There was a significant (P < .0001) dose‐dependent response for PASI90 (week 12); more patients achieved PASI90 in the bimekizumab groups (46.2%‐79.1%) than patients in the placebo group (0%; P < .0001 all doses). Across all doses, there were significant improvements from baseline for all secondary endpoints (PASI90 week 8, PASI75 week 12, PASI100 week 12, and Investigators Global Assessment clear or almost clear weeks 8 and 12; P ≤ .0003) compared with placebo. More bimekizumab‐treated patients than placebo‐treated patients achieved PASI100 (week 12) (27.9%‐60.0% vs 0%; P ≤ .0002 all doses). Treatment‐emergent adverse events were reported by 126 of 208 (61%) bimekizumab‐treated patients and 15 of 42 (36%) placebo‐treated patients. Limitations No active comparator. Conclusion Dual neutralization of IL‐17A and IL‐17F with bimekizumab provided rapid and substantial clinical improvements in patients with psoriasis, with no unexpected or dose‐related safety findings.

• Publication year

  2018

• Venue

  Journal of American Academy of Dermatology

• Publication date

  2018-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jaad.2018.03.037PMID 29609013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 699 Dual IL-17A and IL-17F inhibition with bimekizumab provides evidence for IL-17F contribution to immune-mediated inflammatory skin response

  2017cited by this paper
• THU0038 Bimekizumab dual inhibition of IL-17A and IL-17F provides evidence of IL-17F contribution to chronic inflammation in disease-relevant cells

  2017cited by this paper
• Efficacy and safety of guselkumab, an anti‐interleukin‐23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double‐blinded, placebo‐ and active comparator–controlled VOYAGE 1 trial

  2017cited by this paper
• Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

  2017cited by this paper
• First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

  2017cited by this paper
• 02.13 Il-17f contributes to human chronic inflammation in synovial tissue: Preclinical evidence with dual il-17a and il-17f inhibition with bimekizumab in psoriatic arthritis

  2017cited by this paper
• Risankizumab versus Ustekinumab for Moderate‐to‐Severe Plaque Psoriasis

  2017cited by this paper
• Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation

  2017cited by this paper
• Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

  2016cited by this paper
• A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

  2016cited by this paper
• Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

  2015cited by this paper
• Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.

  2015cited by this paper
• IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies

  2015cited by this paper
• Secukinumab in plaque psoriasis--results of two phase 3 trials.

  2014cited by this paper
• The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries

  2014cited by this paper
• Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?

  2014cited by this paper
• Global epidemiology of psoriasis: a systematic review of incidence and prevalence.

  2013cited by this paper
• Psoriasis severity and the prevalence of major medical comorbidity: a population-based study.

  2013cited by this paper
• Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E.

  2011cited by this paper
• Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.

  2010cited by this paper
• Interleukin-17 and type 17 helper T cells.

  2009cited by this paper
• Mechanisms of Disease: Psoriasis.

  2009cited by this paper
• Regulation of inflammatory responses by IL-17F

  2008cited by this paper
• The Human IL-17F/IL-17A Heterodimeric Cytokine Signals through the IL-17RA/IL-17RC Receptor Complex

  2008cited by this paper
• Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

  2007cited by this paper
• Pathogenesis and therapy of psoriasis

  2007cited by this paper
• A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

  2005cited by this paper
• The Psychosocial Burden of Psoriasis

  2005cited by this paper
• Cutting Edge: IL-17D, a Novel Member of the IL-17 Family, Stimulates Cytokine Production and Inhibits Hemopoiesis1

  2002cited by this paper
• Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

  2001cited by this paper
• IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo.

  2001cited by this paper
• IL‐17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL‐17F, and implications for receptor binding

  2001cited by this paper
• Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family.

  2000cited by this paper
• T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines

  1996cited by this paper

• A novel oral interleukin-23 receptor antagonist peptide, icotrokinra, for moderate-to- severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.

  2026cites this paper
• Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review

  2025cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2025cites this paper
• Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta-analysis

  2025cites this paper
• Biologic Therapy and Superficial Fungal Infection Risk in Moderate‐to‐Severe Psoriasis: A Meta‐Analysis

  2025cites this paper
• Assessing the clinical progress of the bispecific nanobody sonelokimab

  2025cites this paper
• Safety, Pharmacokinetics, and Efficiency of JS005, a Novel Anti-interleukin-17A Monoclonal Antibody, in Healthy Chinese Adults and Patients with Moderate to Severe Psoriasis

  2025cites this paper
• From the Masterclasses in Dermatology 2024 Meeting: Updates in Psoriasis Treatments.

  2025cites this paper
• Biologics and small molecules for psoriasis: current and future progress

  2025cites this paper
• Large‐Scale Blood Proteomic Analysis Across Different Inflammatory Skin Conditions Reveals Extensive Immune Dysregulation With Distinct Biomarker Profiles

  2025cites this paper
• Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis

  2025cites this paper
• Inflammation-Driven Molecular Ageing in Chronic Inflammatory Skin Diseases: Is There a Role for Biologic Therapies?

  2025cites this paper
• Immunopeptidome analysis reveals SERPINB3 as an autoantigen driving eczematized psoriasis

  2025cites this paper
• The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

  2024cites this paper
• The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis.

  2024cites this paper
• Bimekizumab for the treatment of psoriasis.

  2024cites this paper
• Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.

  2024cites this paper
• Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets

  2024cites this paper
• The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

  2024influential citation
• Synovial microenvironment-influenced mast cells promote the progression of rheumatoid arthritis

  2024cites this paper
• Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis

  2024cites this paper
• Bimekizumab-bkzx for the Treatment of Plaque Psoriasis: A Drug Review

  2024cites this paper
• A transdermal delivery system using microneedle patches containing poly(lactic-co-glycolic)-encapsulated acitretin nanoparticles for topical and extended treatment

  2024cites this paper
• Performance of two large language models for data extraction in evidence synthesis

  2024cites this paper
• Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review.

  2024cites this paper
• IL-17A enhances the inflammatory response of glaucoma through Act1/TRAF6/NF-κB pathway.

  2024cites this paper
• The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• Effects on peripheral and central nervous system of key inflammatory intercellular signalling peptides and proteins in psoriasis

  2024cites this paper
• Unveiling IL-17's role: Therapeutic insights and cardiovascular implications.

  2024cites this paper
• Serious adverse events associated with systemic treatments for psoriasis: a network meta-analysis of observational studies and randomized controlled trials

  2024cites this paper
• Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition.

  2024cites this paper
• Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives

  2023cites this paper
• Immune-mediated inflammatory diseases: Common and different pathogenic and clinical features.

  2023cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2023cites this paper
• Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease.

  2023cites this paper
• Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis

  2023cites this paper
• Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation

  2023influential citation
• Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement

  2023cites this paper
• Updates in treatment and impact of nail psoriasis

  2023cites this paper
• Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

  2023cites this paper
• Research Progress of Interleukin-17 in Related Skin Diseases

  2023cites this paper
• Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials

  2023cites this paper
• Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials

  2023cites this paper
• New insights into the function of Interleukin-25 in disease pathogenesis

  2023cites this paper
• Acrodermatitis continua of Hallopeau successfully treated with bimekizumab: A case report

  2023cites this paper
• Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review

  2023cites this paper
• Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study

  2023cites this paper
• Keratinocyte FABP5-VCP complex mediates recruitment of neutrophils in psoriasis

  2023cites this paper
• A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and biological agents

  2023cites this paper
• Risk of candidiasis associated with interleukin-17 inhibitors: Implications and management

  2023influential citation
• The IL-17 family in diseases: from bench to bedside

  2023cites this paper
• Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis

  2023cites this paper
• Data extraction for evidence synthesis using a large language model: A proof‐of‐concept study

  2023cites this paper
• Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment.

  2023cites this paper
• Bimekizumab Sebagai Pengobatan Pilihan Psoriasis Vulgaris Tipe Plak

  2023cites this paper
• Expression and activity of IL-17 receptor subunits in human cutaneous cells as targets for anti-IL-17 therapeutic antibodies.

  2022cites this paper
• Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review

  2022cites this paper
• Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study

  2022cites this paper
• Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis

  2022cites this paper
• Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge

  2022influential citation
• Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis

  2022cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2022cites this paper
• Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis

  2022cites this paper
• Interleukin 17, the double-edged sword in atherosclerosis.

  2022cites this paper
• Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature

  2022cites this paper
• Characterization of Blood Mucosal‐Associated Invariant T Cells in Patients With Axial Spondyloarthritis and of Resident Mucosal‐Associated Invariant T Cells From the Axial Entheses of Non‐Axial Spondyloarthritis Control Patients

  2022cites this paper
• Update on the etiopathogenesis of psoriasis (Review)

  2022cites this paper
• Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study

  2022cites this paper
• Pathogenesis, multi-omics research, and clinical treatment of psoriasis.

  2022cites this paper
• Review of bimekizumab in the treatment of psoriasis

  2022cites this paper
• Latest Advances for the Treatment of Chronic Plaque Psoriasis with Biologics and Oral Small Molecules

  2021cites this paper
• Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

  2021cites this paper
• Additional Biologic Therapeutics

  2021cites this paper
• Psoriasis: Recent progress in molecular‐targeted therapies

  2021cites this paper
• Vergleich der Wirksamkeit und Sicherheit von Biologika bei mittelstark bis stark ausgeprägter Plaque‐Psoriasis: Metaanalyse multipler Therapien

  2021cites this paper
• The role of ixekizumab in non-radiographic axial spondyloarthritis

  2021cites this paper
• IL-25 (IL-17E) in epithelial immunology and pathophysiology.

  2021cites this paper
• Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.

  2021cites this paper
• Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities

  2021cites this paper
• Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.

  2021cites this paper
• Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.

  2021cites this paper
• Cytokine “fine tuning” of enthesis tissue homeostasis as a pointer to spondyloarthritis pathogenesis with a focus on relevant TNF and IL-17 targeted therapies

  2021cites this paper
• Major Role of the IL17/23 Axis in Psoriasis Supports the Development of New Targeted Therapies

  2021cites this paper
• Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.

  2021cites this paper
• Human rights and fair access to COVID-19 vaccines: the International AIDS Society–Lancet Commission on Health and Human Rights

  2021cites this paper
• IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study.

  2021cites this paper
• Nanobody cytokine blockers in psoriasis.

  2021cites this paper
• Out of the shadow of interleukin-17A: the role of interleukin-17F and other interleukin-17 family cytokines in spondyloarthritis

  2021cites this paper
• Newer Therapies in Psoriasis.

  2021cites this paper
• From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment

  2021cites this paper
• Depression and Obesity in Patients With Psoriasis and Psoriatic Arthritis: Is IL-17-Mediated Immune Dysregulation the Connecting Link?

  2021cites this paper
• Gastroenterological safety of IL-17 inhibitors: a systematic literature review

  2021cites this paper
• Immunomodulatory Properties of Umbilical Cord Blood-Derived Small Extracellular Vesicles and Their Therapeutic Potential for Inflammatory Skin Disorders

  2021influential citation
• A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab

  2021cites this paper
• Dual inhibition of IL-17A and IL-17F in psoriatic disease

  2021cites this paper
• Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

  2021cites this paper
• Bimekizumab for the Treatment of Psoriasis

  2021cites this paper
• Psoriasis medications: The future

  2021cites this paper
• Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study

  2021cites this paper
• Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice

  2021cites this paper